Vaccines News Stories
Below are key excerpts of revealing news articles on vaccine controversies from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.
The claim: Florida Gov. Ron DeSantis's executive order allows civilians to receive a coronavirus vaccination and 'it might be happening.' An Instagram post from April claims an executive order signed by Florida Gov. Ron DeSantis allows the state to require its "civilians" to receive a coronavirus vaccination. The Instagram post [refers] to an executive order issued by DeSantis on March 23. It mandates travelers arriving in Florida self-quarantine for "14 days from the time of entry into the state of Florida or the duration of the person's presence in the state of Florida, whichever is shorter." Section B of the executive order ... references powers given under section 5 of Florida statute 381.00315, which details the proceedings of public officials in the time of a public health emergency. The statute says the government, amid a public health emergency when imposing isolation or quarantine, can adopt rules such as "tests or treatment, including vaccination, for communicable disease required before employment or admission to the premises or to comply with an isolation or a quarantine." It is true that Florida statute 381.00315, as cited in DeSantis's executive orders, makes it legal to order an individual to be vaccinated, among other public safety measures, during a public health emergency. But because there is not yet a coronavirus vaccine, it is false to imply this action is imminent.
Note: The Instagram post did not say that the vaccine mandate is imminent. Notice how far the media will stretch to discredit valid information. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus from reliable major media sources.
When pharmaceutical company Moderna issued a press release about the promising results of its Phase I clinical trial for a coronavirus vaccine, the media and the markets went wild. Upon examining Moderna's non-peer reviewed press release, the actual data on the vaccine's success is ... flimsy. Of the 45 patients who received the vaccine, the data on "neutralising antibody data are available only for the first four participants in each of the 25-microgram and 100-microgram dose level cohorts." In other words, that means that when it comes to finding out whether the vaccine elicits an antibody response that could potentially fight the coronavirus, they only had data on eight patients. That's not enough to do any type of statistical analysis and it also brings into question the status of the other 37 patients who also received the vaccine. Moderna's messenger RNA vaccine ... uses a sequence of genetic RNA material produced in a lab that, when injected into your body, must invade your cells and hijack your cells' protein-making machinery called ribosomes to produce the viral components that subsequently train your immune system to fight the virus. There are unique and unknown risks to messenger RNA vaccines, including the possibility that they generate strong type I interferon responses that could lead to inflammation and autoimmune conditions. Messenger RNA vaccines have never before been brought to market for human patients.
Note: To learn about the serious risks and dangers of these mRNA vaccines, don't miss the vitally important information given by Christiane Northrup, MD, in the first five minutes of this highly revealing video. Reader's Digest named Dr. Northrup one of "The 100 Most Trusted People in America." Dr. Northrup's work has been featured on The Oprah Winfrey Show, the Today Show, NBC Nightly News, Good Morning America, 20/20, and The Dr. Oz Show. For more, see concise summaries of revealing news articles on the coronavirus and vaccines from major media sources.
The chairman and CEO of Pfizer, Albert Bourla, sold $5.6 million worth of stock in the pharmaceutical company on Monday. The sale took place on the same day Pfizer announced that its experimental coronavirus vaccine candidate was found to be more than 90% effective. Bourla's sale of Pfizer stock was part of a trading plan set months in advance. Known as 10b5-1 plans, they essentially put stock trades on autopilot. Executives are supposed to adopt these plans only when they are not in possession of inside information that can affect a company's stock price. On Aug. 19, Bourla implemented his stock-trading plan. The next day, Aug. 20, Pfizer issued a press release ... confirming that Pfizer and its German partner, BioNTech, were "on track to seek regulatory review" for its vaccine candidate. Daniel Taylor, an expert in insider trading ... told NPR that the close timing between the adoption of Bourla's stock plan and the press release looked "very suspicious." "It's wholly inappropriate for executives at pharmaceutical companies to be implementing or modifying 10b5-1 plans the business day before they announce data or results from drug trials," Taylor said. The stock sales by Pfizer's CEO brought to mind similar concerns with another coronavirus vaccine-maker, Moderna. Multiple executives at Moderna adopted or modified their stock-trading plans just before key announcements about the company's vaccine. Those executives have sold tens of millions of dollars in Moderna stock.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma profiteering from reliable major media sources.
Moderna CEO St©phane Bancel more than tripled the number of his company shares to be sold through an executive stock plan that was changed just days after the biotech in May announced positive early results for its coronavirus vaccine. Moderna's shares spiked on the May news, rising 30% in just one day. After seeking the executive stock plan change in May, Bancel sold more than 72,000 Moderna shares in the first 16 days of July, generating nearly $4.8 million for the executive. That was more than triple the 22,000 shares he had previously scheduled to sell during the same period through the company's executive trading plan. Another top Moderna executive, President Stephen Hoge, also had his pre-programmed executive trading plan reset around the same time. The change allowed him to sell $1.9 million worth of Moderna stock in the first two weeks of July. The executives' ... sales were made through what are known as 10b5-1 stock plans. These arrangements must be set up or amended at least 30 days before any transactions are executed; they are commonly used at publicly traded companies to help shield executives from potential claims of insider trading. The fact that the plans were changed during the pandemic as news was emerging about the company's closely watched coronavirus vaccine raises new questions about how Moderna executives have pocketed millions of dollars in recent months.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma profiteering from reliable major media sources.
Pfizer is expected to seek federal permission to release its Covid-19 vaccine by the end of November. The vaccine, and likely most others, will require two doses to work, injections that must be given weeks apart. The shots will cause enervating flu-like side effects – including sore arms, muscle aches and fever – that could last days and temporarily sideline some people from work or school. And even if a vaccine proves 90 percent effective ... 1 in 10 recipients would still be vulnerable. That means, at least in the short term, as population-level immunity grows, people can't stop social distancing and throw away their masks. Left out so far ... has been a large-scale plan to communicate effectively about those issues in advance, said Saad Omer, director of the Yale Institute for Global Health. Such broad-based outreach will be necessary in a country where, as of mid-October, only half of Americans said they'd be willing to get a Covid-19 vaccine. "We are asking people to take a vaccine that is going to hurt," said Dr. William Schaffner, a professor of preventive medicine and health policy at Vanderbilt. "There are lots of sore arms and substantial numbers of people who feel crummy, with headaches and muscle pain, for a day or two." Persuading people who experience those symptoms to return in three to four weeks for a second dose – and a second round of flu-like symptoms – could be a tough sell, Schaffner said. A professor of internal medicine and epidemiology at University of Iowa [suggested] that essential workers should be granted three days of paid leave after they're vaccinated.
Important Note: Learn about the serious dangers of these mRNA vaccines through the vitally important information given by Christiane Northrup, MD, in the first five minutes of this revealing video. Dr. Northrup's work has been featured on NBC Nightly News, Good Morning America, Oprah, Dr. Oz, and more. And an informative article in the UK's Independent by another medical doctor states, "There are unique and unknown risks to messenger RNA vaccines, including the possibility that they ... could lead to inflammation and autoimmune conditions."
As of Sunday, a total [of] 1,231 people in South Korea reported side effects after getting the flu shot this year, according to health authorities. Last week, the Korean Medical Association "recommended to withhold vaccination for one week," but clarified it was not suggesting vaccinations be stopped. Of the 59 people who died after receiving the flu vaccine this year (up from 48 on Saturday), 46 of those deaths were believed to have no connection to the flu shot. An investigation into the 13 remaining fatalities has been launched, the Korea Disease Control and Prevention Agency (KDCA) revealed. More than 9.4 million people in South Korea have received the flu shot so far since this year's vaccination program began in September. The KDCA noted the latest number of deaths following the flu vaccination is not greater than previous years. Last year, 1,531 people aged 65 years and older died within seven days after receiving a flu shot, according to the KDCA. President Moon noted Monday: "This year, it is necessary to expand flu vaccinations not only to prevent the flu, but also to prevent simultaneous infection and spread of the flu and coronavirus."
Note: How much can we trust authorities who are clearly biased towards promoting vaccines? For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.
Previous vaccines have taken a decade or more to develop, and more than half of the past 20 years have failed in clinical trials. However, four [COVID-19] vaccine candidates have entered the final phase of clinical trials prior to approval by the Food and Drug Administration. Operation Warp Speed ... organized government agencies and private companies with the goal of developing, manufacturing and distributing hundreds of millions of vaccine doses, with starting doses to be available by early 2021. At the head of the operation is Moncef Slaoui, a Moroccan-born Belgian-American scientist. Operation Warp Speed … has invested in six vaccine candidates (Moderna, Pfizer / BioNTech, Johnson & Johnson, AstraZeneca, Novavax, and Sanofi / GSK) with the hope that at least one ... will prove safe and effective in clinical trials. Four of the six vaccine candidates have already been shown to be safe and effective in the first two test phases, which test whether the vaccinations produce so-called neutralizing antibodies. Serious health problems regularly arise during vaccination attempts. "We know how to distribute vaccines to any location in the US," says Slaoui. "It happens every year for flu and shingles." Tracking systems need to be "incredibly precise" to ensure that patients are each given two doses of the same vaccine and to monitor them for adverse health effects. Operation Warp Speed … has selected medical distributor McKesson and cloud operators Google and Oracle to collect and track vaccine data.
Note: The above article is also available here. Don't miss this excellent article which raises many important questions about this operation. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.
The Trump administration has compared Operation Warp Speed's crash program to develop a COVID-19 vaccine to the Manhattan Project. And like the notoriously secretive government project to make the first atomic bomb, the details of Operation Warp Speed's work may take a long time to unravel. One reason is that Operation Warp Speed is issuing billions of dollars' worth of coronavirus vaccine contracts to companies through a nongovernment intermediary, bypassing the regulatory oversight and transparency of traditional federal contracting mechanisms, NPR has learned. Instead of entering into contracts directly with vaccine makers, more than $6 billion in Operation Warp Speed funding has been routed through a defense contract management firm called Advanced Technologies International, Inc. ATI then awarded contracts to companies working on COVID-19 vaccines. As a result, the contracts between the pharmaceutical companies and ATI may not be available through public records requests, and additional documents are exempt from public disclosure for five years. [Robin] Feldman, of UC Hastings, says the administration's comparison of Operation Warp Speed to the Manhattan Project is troubling. "I think that's completely the wrong image," she says. "The right analogy, I think, for Operation Warp Speed is the penicillin effort in World War II. We can do a lot of good together, but we have to make sure pharma companies aren't taking advantage of the crisis."
Note: Read an excellent article showing how most of these contracts are linked to the CIA and DHS and more. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and the coronavirus from reliable major media sources.
Whether the coronavirus vaccine developed by Moderna succeeds or not, executives at the small biotech company have already made tens of millions of dollars by cashing in their stock. An NPR examination of official company disclosures has revealed additional irregularities and potential warning signs. Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock; Chief Medical Officer Tal Zaks has sold around $60 million; and President Stephen Hoge has sold more than $10 million. The stock sales first came to widespread notice after Moderna announced positive early data from a vaccine trial in May. At that point, the company's share price jumped and official disclosures showed executives cashing in their shares for millions of dollars. Advocates have questioned whether it's appropriate for executives to privately profit before bringing the vaccine to market, especially when American taxpayers have committed roughly $2.5 billion to the company's vaccine development. Moderna says its executives pre-scheduled their stock sales long in advance. Those schedules - known as 10b5-1 plans - can act as a defense to charges of insider trading. But the plans have to be put in place when executives do not have confidential inside information. NPR has found multiple executives adopted or modified their plans just before key announcements about the company's vaccine. That has raised questions about whether they were aware of nonpublic information when they planned their stock trades.
Note: Explore a revealing NBC article titled “Secret, powerful panels will pick Covid-19 vaccine winners.” For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma corruption from reliable major media sources.
AstraZeneca revealed details of its large coronavirus vaccine trials on Saturday, the third in a wave of rare disclosures by drug companies under pressure to be more transparent about how they are testing products that are the world’s best hope for ending the pandemic. Polls are finding Americans increasingly wary of accepting a coronavirus vaccine. Experts have been particularly concerned about AstraZeneca’s vaccine trials, which began in April in Britain, because of the company’s refusal to provide details about serious neurological illnesses in two participants, both women, who received its experimental vaccine in Britain. Those cases spurred the company to halt its trials twice, the second time earlier this month. The studies have resumed in Britain, Brazil, India and South Africa, but are still on pause in the U.S. About 18,000 people worldwide have received AstraZeneca’s vaccine so far. The company has released few details about the two cases of serious illness in its trial. The first participant received one dose of the vaccine before developing inflammation of the spinal cord, known as transverse myelitis. The condition can cause weakness in the arms and legs, paralysis, pain and bowel and bladder problems. The company said it had not confirmed a diagnosis in the second case, a participant who got sick after the second dose of the vaccine. A person familiar with the situation who spoke with The Times on the condition of anonymity said the participant’s illness had been pinpointed as transverse myelitis.
Note: Why won’t the company let the two who became seriously ill speak to the media? And why initially did they hide the fact that the illnesses were serious? And why are top vaccine executives now dumping their shares of stocks? For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma corruption from reliable major media sources.
On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U.S. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. The race is on to develop a coronavirus vaccine, and some companies and investors are betting that the winners stand to earn vast profits from selling hundreds of millions — or even billions — of doses to a desperate public. Across the pharmaceutical and medical industries, senior executives and board members ... are making millions of dollars after announcing positive developments, including support from the government, in their efforts to fight Covid-19. After such announcements, insiders from at least 11 companies — most of them smaller firms whose fortunes often hinge on the success or failure of a single drug — have sold shares worth well over $1 billion since March. Senior officials appear to be pouncing on opportunities to cash out. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. Some companies are attracting government scrutiny for ... using their associations with Operation Warp Speed as marketing ploys. Vaxart’s news release declared: “Vaxart’s Covid-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed.” But Vaxart is not among the companies selected to receive significant financial support from Warp Speed.
Note: MSN strangely removed this article a few days after posting it. A similar article by the New York Times titled "The race for a coronavirus vaccine is making some corporate insiders very rich" is available here. For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption and the coronavirus from reliable major media sources.
One by one, vaccine developers at a White House roundtable convened by President Donald Trump in early March pitched their product as a viable solution to the coronavirus. Stéphane Bancel of Moderna Inc. glanced across the table at the nation's top infectious disease expert, Dr. Anthony Fauci, and said he is "very proud to be working with the US government and to have already sent, in only 42 days from the sequence of the virus, our vaccine to Dr. Fauci's team at the NIH." Bancel went on to say that he needed just "a few months" to start phase two of a three-part clinical trial of the sort that typifies vaccine development. (The entire process often takes more than a decade.) The day after the roundtable, the FDA green-lit Moderna's product for trial, making it the first vaccine candidate to advance to the first phase of a clinical study, in which an as-yet unapproved vaccine is injected into the arms of a small group of 45 human volunteers. The effort received another boost on April 16, when the federal Biomedical Advanced Research and Development Authority (BARDA) awarded Moderna up to $483 million to accelerate the development and manufacturing of the vaccine. The FDA allowed Moderna's RNA vaccine ... to essentially gloss over the animal-testing that typically precede clinical trials in humans. [Moderna's former director of chemistry Dr. Suhaib] Siddiqi said this is cause for alarm. "I would not let that [vaccine] be injected in my body," he said. "I would demand: Where is the toxicity data from the lab?"
Note: Read a New York Times/MSN article titled "Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine." For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.
Warren D. Ward, 48, was in high school when the swine flu threat of 1976 swept the U.S. A relative died in the 1918 flu pandemic, and the 1976 illness was feared to be a direct descendant of the deadly virus. The government wanted everyone to get vaccinated, Ward said. But the epidemic never really broke out. It was a threat that never materialized. The episode began in February 1976, when an Army recruit at Ft. Dix, N.J., fell ill and died from a swine flu virus thought to be similar to the 1918 strain. Several other soldiers at the base also became ill. The CDC ... called on President Ford and Congress to begin a mass inoculation. The $137-million program began in early October, but within days reports emerged that the vaccine appeared to increase the risk for Guillain-Barre syndrome, a rare neurological condition that causes temporary paralysis but can be fatal. More than 40 million Americans ... received the swine flu vaccine before the program was halted in December after 10 weeks. More than 500 people are thought to have developed Guillain-Barre syndrome after receiving the vaccine; 25 died. Only about 200 cases of swine flu and one death were ultimately reported. No one completely understands the causes of Guillain-Barre, but the condition can develop after a bout with infection or following surgery or vaccination. The federal government paid millions in damages. The pandemic, which some experts estimated at the time could infect 50 million to 60 million Americans, never unfolded.
Note: For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.
Louis Pasteur, one of the legendary figures in the history of science, lied about his research, stole ideas from a competitor and was deceitful in ways that would now be regarded as scientific misconduct if not fraud, according to a revisionist history published this month. "The Private Science of Louis Pasteur," by Dr. Gerald L. Geison of Princeton University, is based on an examination of Pasteur's 102 laboratory notebooks. Pasteur ... tried to reduce the virulence of microbes by exposing them to oxygen in order to make them suitable for vaccination. But in developing a vaccine against anthrax ... Pasteur adapted a method he had used a year earlier to produce a vaccine against chicken cholera. To head off competitors, Pasteur had purposely withheld reporting the simple method he used to prepare the chicken cholera vaccine. Pasteur impulsively accepted a public challenge to carry out the world's first public trial of any experimental vaccine. Pasteur's assistants injected his formula into 25 sheep, left another 25 unprotected and then injected all 50 with virulent anthrax bacteria. Only the vaccinated sheep survived. But, the notebooks show, Pasteur lied when he suggested publicly that his dramatically successful vaccine had been developed by exposing anthrax bacteria to oxygen. In fact he ... made his vaccine by secretly relying on a technique used by a rival, Jean-Joseph Toussaint. Eventually, Pasteur's oxygen method did produce an anthrax vaccine, but only after he had won a monopoly to produce the vaccine.
Note: For more on how scientific myths are perpetuated, see this fascinating article. For more along these lines, see concise summaries of deeply revealing news articles on corruption in science from reliable major media sources.
Moderna set off a frenzy on Wall Street earlier this month when it announced positive, preliminary results from its coronavirus vaccine trial. As the hype grew, the young biotech company and its leading investor wasted no time capitalizing on the briefly surging stock price. Even as critics accused Moderna of overhyping the results released on May 18, a series of transactions were executed before its share price fizzled over the next week. The timing of those deals, former SEC officials said, appear to be "highly problematic" and should be investigated for potential illegal market manipulation. Just hours after revealing the promising vaccine results, Moderna (MRNA) sold 17.6 million shares to the public. That share sale, unveiled after the closing bell on May 18, was priced at $76; Moderna traded at just $48 as recently as May 6. The deal instantly raised $1.3 billion. Two of Moderna's top executives also cashed in on the boom at their company, which had suddenly amassed a $29 billion market value despite the fact it has no marketed products. By the time the selling was disclosed to the public via securities filings, Moderna's stock price had crashed back to Earth. The timing of the transactions - coupled with concerns from some medical experts that Moderna overstated the significance of its Phase 1 vaccine trial - should be investigated by authorities. Thomas Gorman, [a] former SEC official, said the agency should "absolutely" be investigating the situation at Moderna.
Note: Why didn't the media report that the Moderna vaccine trial had a 20% serious injury rate in the high dose group? Learn about this and much more in this revealing article. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
The chief scientist brought on to lead the Trump administration’s vaccine efforts has spent the last several days trying to disentangle pieces of his stock portfolio and his intricate ties to big pharmaceutical interests. The scientist, Moncef Slaoui, is a venture capitalist and a former longtime executive at GlaxoSmithKline. Most recently, he sat on the board of Moderna, a Cambridge, Mass., biotechnology firm with a $30 billion valuation that is pursuing a coronavirus vaccine. He resigned when President Trump named him last Thursday to the new post as chief adviser for Operation Warp Speed, the federal drive for coronavirus vaccines and treatments. Just days into his job, the extent of Dr. Slaoui’s financial interests in drug companies has begun to emerge: The value of his stock holdings in Moderna jumped nearly $2.4 million, to $12.4 million when the company released preliminary, partial data from an early phase of its candidate vaccine trial. Dr. Slaoui did not come on board as a government employee. Instead, he is on a contract ... that leaves him exempt from federal disclosure rules that would require him to list his outside positions, stock holdings and other potential conflicts. And the contract position is not subject to the same conflict-of-interest laws and regulations that executive branch employees must follow. Dr. Slaoui ... is not the first Trump administration official with close relationships to drug and health care companies. Alex M. Azar II, the health and human services secretary, is a former Eli Lilly executive.
Note: If the above link fails, this article is also available here. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in Big Pharma from reliable major media sources.
It might not be until fall 2021 that Americans "can be completely safe" from COVID-19, Bill Gates said in a Tuesday interview with Judy Woodruff on PBS Newshour. That's because it will take more than a year before a vaccine can be developed and deployed, according to researchers working to develop a treatment for COVID-19. "The vaccine is critical, because, until you have that, things aren't really going to be normal," the billionaire philanthropist told Woodruff. "They can open up to some degree, but the risk of a rebound will be there until we have very broad vaccination." Social distancing is helping to lower the number of COVID-19 cases. The goal, Gates explained, is to get that number down to a point where "contact tracing" (a process in which those within close contact with an infected person are closely monitored) can be done, in order to maintain necessary quarantines. To understand what life in the U.S. will look like six to 12 months from now, Gates suggested China as a good model. "They are sending people back to work, but they're wearing masks. They're checking temperatures. They're not doing large sporting events. And so they have been able to avoid a large rebound," he said. Beyond that, "returning to some semblance of normal," as Woodruff put it, can be predicted by watching the behaviors of other countries. Sweden, for example, isn't "locking down quite as much," so their experience will be informative, Gates explained.
Note: In this video interview, Gates says we need to vaccinate everyone in the world. And he wants indemnity in case the vaccine he sponsors ends up killing or injuring many. Learn more about how Gates uses his billions to gain political power. And don't miss this most important video focused on how he is using fear of the virus to promote his agenda to require a "digital certificate" to ensure they've been vaccinated. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus pandemic from reliable major media sources.
Bill Gates ... just called for a complete and utter shutdown and quarantining of the entire American nation. Despite urging from public health experts, Gates wrote in a Washington Post opinion piece, some states and counties havent shut down completely. This is a recipe for disaster. Because people can travel freely across state lines, so can the virus. The countrys leaders need to be clear: Shutdown anywhere means shutdown everywhere. Until the case numbers start to go down ... no one can continue business as usual or relax the shutdown. He then added that the impacts of the new coronavirus could linger another 18 months or so, until a vaccine was developed. For the peons of America, work isnt an option. Its food. Its survival. The fate of a hard-earned dream shouldnt rest with a globalist billionaire whos warning of dire coronavirus consequences to come all the while making hands-over-fist coronavirus money. Its a conflict of interest. WHO didnt announce the coronavirus as a pandemic until the very day after Gates ... made a very large donation to a cause that benefits WHO. In a 2017 piece titled, Meet the worlds most powerful doctor: Bill Gates, Politico wrote: Some billionaires are satisfied with buying themselves an island. Bill Gates got a United Nations health agency. Over the past decade, the worlds richest man has become the World Health Organizations second-biggest donor, second only to the United States. This largesse gives him outsized influence over its agenda. The result, say his critics, is that Gates priorities have become the WHOs.
Very Important Note: To understand how the coronavirus is being used to exert more control over humanity, don't miss this incredibly important video focused on how Bill Gates is using fear around the coronavirus to push through his agenda to vaccinate everyone on the planet and then require a "digital certificate" to ensure they've been vaccinated. For other reliable, verifiable informing demonstrating how Gates' vaccine agenda has already harmed hundreds of thousands of children read this excellent article by Robert F. Kennedy, Jr.
A large scale malaria vaccine study led by the World Health Organization has been criticised by a leading bioethicist for committing a serious breach of international ethical standards. The cluster randomised study in Africa is already under way in Malawi, Ghana, and Kenya, where 720,000 children will receive the RTS,S vaccine, known as Mosquirix, over the next two years. Mosquirix, the worlds first licensed malaria vaccine, was positively reviewed by the European Medicines Agency, but its use is being limited to pilot implementation, in part to evaluate outstanding safety concerns that emerged from previous clinical trials. [Among these concerns] were a rate of meningitis in those receiving Mosquirix 10 times that of those who did not, increased cerebral malaria cases, and a doubling in the risk of death (from any cause) in girls. Charles Weijer, a bioethicist at Western University in Canada, told The BMJ that the failure to obtain informed consent from parents whose children are taking part in the study violates the Ottawa Statement, a consensus statement on the ethics of cluster randomised trials, of which Weijer is the lead author, and the Council for International Organizations of Medical Sciences International Ethical Guidelines. The failure to require informed consent is a serious breach of international ethical standards, he said.
Note: For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.
Two former Merck & Co Inc scientists accusing the drugmaker of falsifying tests of its exclusive mumps vaccine said in a court filing on Monday that Merck is refusing to respond to questions about the efficacy of the vaccine. Attorneys at Constantine Cannon, who represent the scientists, asked U.S. Magistrate Judge Lynne Sitarski of the Eastern District of Pennsylvania to compel Merck to respond to their discovery request, which asks the company to give the efficacy of the vaccine as a percentage. Instead of answering the question ... Merck has been consistently evasive, using cut-and-paste answers saying it cannot run a new clinical trial to determine the current efficacy, and providing only data from 50 years ago. The two scientists, Stephen Krahling and Joan Wlochowski, filed their whistleblower lawsuit in 2010 claiming Merck, the only company licensed by the Food and Drug Administration to sell a mumps vaccine in the United States, skewed tests of the vaccine by adding animal antibodies to blood samples. As a result, they said, Merck was able to produce test results showing that the vaccine was 95 percent effective, even though more accurate tests would have shown a lower success rate. The plaintiffs said these false results kept competitors from trying to produce their own mumps vaccines, since they were unable to match the effectiveness Merck claimed. The case is United States ex rel Krahling et al v. Merck & Co Inc, U.S. District Court, Eastern District of Pennsylvania, No. 10-4374.
Note: Why didn't this get reported widely? A search reveals no major media other than Reuters and WSJ covered this. This article in a local paper states the two whistleblowers were threatened by Merck with jail if they went public with this. It also says all students in a Syracuse University mumps outbreak had been properly vaccinated. This excellent article gives a 2019 update and reveals how the vaccines caused injury in a very high percentage of cases. For more, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.
Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
